Search

Search Results

• CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas^1,2, M. Marchetti^1,3, L. Russo¹, C.J. Tartari¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁵, A. Falanga^1,3 All on behalf of the Hypercan Investigators | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; ³School of Medicine and Surgery, University of Milan Bicocca, Italy; ⁴University Vita-Salute San Raffaele, Milan, Italy; ⁵Fondazione ARTET Onlus, Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.220

  502

  PDF: 0
• 

  PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas^1|2|, D. Romeo¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁴, A. Falanga^1|5|6, M. Marchetti^1|5|6 | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; ³Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁴Fondazione ARTET Onlus, Bergamo, Italy; ⁵ERN EuroBloodNet; ⁶School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.536

  70

  PDF: 17
• 

  PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti^1|2|3, P. Gomez-Rosas^1|4|5, S. Bolognini¹, C. Ticozzi¹, D. Romeo¹, F. Schieppati^1|3, L. Barcella^1|3, F. Petrelli⁶, A. D'Alessio⁷, R. Labianca⁷, A. Falanga^1|2|3 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ³ERN EuroBloodNet; ⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ⁵Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁶Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; ⁷Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.538

  71

  PDF: 17